Your browser doesn't support javascript.
loading
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Chretien, Marie-Lorraine; Corre, Jill; Lauwers-Cances, Valerie; Magrangeas, Florence; Cleynen, Alice; Yon, Edwige; Hulin, Cyrille; Leleu, Xavier; Orsini-Piocelle, Frederique; Blade, Jean-Sebastien; Sohn, Claudine; Karlin, Lionel; Delbrel, Xavier; Hebraud, Benjamin; Roussel, Murielle; Marit, Gerald; Garderet, Laurent; Mohty, Mohamad; Rodon, Philippe; Voillat, Laurent; Royer, Bruno; Jaccard, Arnaud; Belhadj, Karim; Fontan, Jean; Caillot, Denis; Stoppa, Anne-Marie; Attal, Michel; Facon, Thierry; Moreau, Philippe; Minvielle, Stephane; Avet-Loiseau, Hervé.
Afiliação
  • Chretien ML; Department of Hematology, Centre Hospitalier Universitaire, Dijon, France;
  • Corre J; Unit for Genomics in Myeloma, Institut Universitaire du Cancer-Oncopole, and Centre de Recherches sur le Cancer de Toulouse INSERM 1037, Toulouse, France;
  • Lauwers-Cances V; Service d'Epidemiologie, Centre Hospitalier Universitaire, Toulouse, France;
  • Magrangeas F; Unité Mixte de Génomique du Cancer, Centre Hospitalier Universitaire, and INSERM U892, Nantes, France;
  • Cleynen A; Unit for Genomics in Myeloma, Institut Universitaire du Cancer-Oncopole, and Centre de Recherches sur le Cancer de Toulouse INSERM 1037, Toulouse, France;
  • Yon E; Service d'Epidemiologie, Centre Hospitalier Universitaire, Toulouse, France;
  • Hulin C; Department of Hematology, Centre Hospitalier Universitaire, Nancy, France;
  • Leleu X; Department of Hematology, Centre Hospitalier Universitaire, Lille, France;
  • Orsini-Piocelle F; Department of Hematology, Centre Hospitalier, Annecy, France;
  • Blade JS; Department of Hematology, Centre Hospitalier Universitaire, Nancy, France;
  • Sohn C; Department of Hematology, Hopital Inter-Armées, Toulon, France;
  • Karlin L; Department of Hematology, Centre Hospitalier, Toulon, France;
  • Delbrel X; Department of Hematology, Centre Hospitalier, Pau, France;
  • Hebraud B; Department of Hematology, Institut Universitaire du Cancer, Toulouse, France;
  • Roussel M; Department of Hematology, Institut Universitaire du Cancer, Toulouse, France;
  • Marit G; Department of Hematology, Centre Hospitalier Universitaire, Bordeaux, France;
  • Garderet L; Department of Hematology, Centre Hospitalier Universitaire St-Antoine, Paris, France;
  • Mohty M; Department of Hematology, Centre Hospitalier Universitaire St-Antoine, Paris, France;
  • Rodon P; Department of Hematology, Centre Hospitalier, Perigueux, France;
  • Voillat L; Department of Hematology, Centre Hospitalier, Chalon sur Saone, France;
  • Royer B; Department of Hematology, Centre Hospitalier Universitaire, Amiens, France;
  • Jaccard A; Department of Hematology, Centre Hospitalier Universitaire, Limoges, France;
  • Belhadj K; Department of Hematology, Centre Hospitalier Universitaire, Créteil, France;
  • Fontan J; Department of Hematology, Centre Hospitalier Universitaire, Besançon, France;
  • Caillot D; Department of Hematology, Centre Hospitalier Universitaire, Dijon, France;
  • Stoppa AM; Department of Hematology, Institut Paoli Calmettes, Marseille, France; and.
  • Attal M; Department of Hematology, Institut Universitaire du Cancer, Toulouse, France;
  • Facon T; Department of Hematology, Centre Hospitalier Universitaire, Lille, France;
  • Moreau P; Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.
  • Minvielle S; Unité Mixte de Génomique du Cancer, Centre Hospitalier Universitaire, and INSERM U892, Nantes, France;
  • Avet-Loiseau H; Unit for Genomics in Myeloma, Institut Universitaire du Cancer-Oncopole, and Centre de Recherches sur le Cancer de Toulouse INSERM 1037, Toulouse, France;
Blood ; 126(25): 2713-9, 2015 Dec 17.
Article em En | MEDLINE | ID: mdl-26516228
ABSTRACT
The prognosis of multiple myeloma is mainly dependent upon chromosomal changes. The 2 major abnormalities driving poor outcome are del(17p) and t(4;14). However, the outcome of these high-risk patients is not absolutely uniform, with some patients presenting long survival. We hypothesized that these better outcomes might be related to concomitant "good-risk" chromosomal changes exploring hyperdiploidy. We analyzed a large series of 965 myeloma patients, including 168 patients with t(4;14) and 126 patients with del(17p), using high-throughput single-nucleotide polymorphism arrays after plasma cell sorting. As expected, trisomic chromosomes were highly associated. Using the LASSO model, we found that only chromosome 3, when trisomic, was associated with a longer progression-free survival and that 3 trisomies modulated overall survival (OS) in myeloma patients trisomies 3 and 5 significantly improved OS, whereas trisomy 21 worsened OS. In patients with t(4;14), trisomies 3 and/or 5 seemed to overcome the poor prognosis. For the first time, using a specific modeling approach, we show that not all trisomies display the same prognostic impact. This finding could be important for routine assessment of prognosis in myeloma, and some high-risk patients with a traditional evaluation could in fact be standard-risk patients.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trissomia / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trissomia / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2015 Tipo de documento: Article